Tranexamic acid for the treatment of heavy menstrual bleeding: Efficacy and safety

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 413-421

  Leminen, Henri ^a   Hurskainen, Ritva ^a,b  

^a HYVINKÄÄ HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Heavy menstrual bleeding; Menorrhagia; Tranexamic acid

Indexed keywords

DANAZOL; DESMOPRESSIN; ETAMSYLATE; FLURBIPROFEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; PLACEBO; TRANEXAMIC ACID;

ARTHRALGIA; BACKACHE; BLEEDING; CINAHL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIUM ABLATION; FATIGUE; HEADACHE; HEAVY MENSTRUAL BLEEDING; HUMAN; IDIOPATHIC DISEASE; INFORMATION RETRIEVAL; MEDICAL LITERATURE; MEDLINE; MENSTRUAL DISCOMFORT; MENSTRUATION DISORDER; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NOSE CONGESTION; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; STATISTICAL ANALYSIS; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VIRAL UPPER RESPIRATORY TRACT INFECTION;

EID: 84866065917     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183-194.
2. Rees M. Menorrhagia. Br Med J (Clin Res Ed). 1987;294(6574): 759-762.
3. Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45(3):320-351.
4. Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM. Determination of total menstrual blood loss. Fertil Steril. 2001;76(1):125-131. http://www.fda.gov [homepage on the Internet]
5. US Food and Drug Administration. Drugs@FDA: Lysteda (tranexamic acid) label information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022430s002lbl.pdf. Accessed March 19, 2012.
6. Wellington K, Wagstaff AJ. Tranexamic acid: A review of its use in the management of menorrhagia. Drugs. 2003;63(13):1417-1433.
7. Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol. 2002;68(5):307-309.
8. Woo KS, Tse LK, Woo JL, Vallance-Owen J. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract. 1989;43(12):465-466.
9. Dawood M, Huang J. Uterine vascular function and menstruation. Curr Obstet Gynaecol. 1998;8(2):66-72.
10. Markee JE. Morphological basis for menstrual bleeding; relation of regression to the initiation of bleeding. Bull N Y Acad Med. 1948;24(4): 253-268.
11. Rogers PA, Lederman F, Taylor N. Endometrial microvascular growth in normal and dysfunctional states. Hum Reprod Update. 1998;4(5): 503-508.
12. Ferenczy A, Bertrand G, Gelfand MM. Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol. 1979;133(8):859-867.
13. Smith SK, Abel MH, Kelly RW, Baird DT. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1981;88(4):434-442.
14. Wang IY, Fraser IS, Barsamian SP, et al. Endometrial lysosomal enzyme activity in ovulatory dysfunctional uterine bleeding, IUCD users and post-partum women. Mol Hum Reprod. 2000;6(3):258-263.
15. Rybo G. Plasminogen activators in the endometrium. II. Clinical aspects. Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood loss. Acta Obstet Gynecol Scand. 1966;45(4):429-450.
16. Hefnawi F, Saleh A, Kandil O, El-Sheikha Z, Hassanein M, Askalani H. Fibrinolytic activity of menstrual blood in normal and menorrhagic women and in women wearing the lippes loop and the cu-T (200). Int J Gynaecol Obstet. 1979;16(5):400-407.
17. Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand. 1994; 73(3):274-277.
18. Dockeray CJ, Sheppard BL, Daly L, Bonnar J. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol. 1987; 24(4):309-318.
19. Benoni G, Björkman S, Fredin H. Application of pharmacokinetic data from healthy volunteers for the prediction of plasma concentrations of tranexamic acid in surgical patients. Clin Drug Invest. 1995;10(5): 280-287.
20. Eriksson O, Kjellman H, Pilbrant A, Schannong M. Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol. 1974;7(5):375-380.
21. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20(1): 65-72.
22. http://www.ema.europa.eu [homepage on the Internet].
23. European Medicines Agency. Committee for proprietary medicinal products (CPMP) opinion following an article 10 referral: CYKLO-f (tranexamic acid). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Cyklo-f/human_referral_000097.jsp&mid=WC0b01ac0580024e9a#. Accessed March 19, 2012.
24. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand. 1988;67(7):645-648.
25. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: Randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996;313(7057):579-582.
26. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J. 1970;4(5729): 214-216.
27. Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol. 2011;205(4):319. e1-319. e7.
28. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: A prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009;145(2):212-220.
29. Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol. 2006;26(7): 673-678.
30. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstet Gynecol. 2010;116(4):865-875.
31. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164(3):879-883.
32. Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA): A double blind investigation. Acta Obstet Gynecol Scand. 1967;46(4):572-580.
33. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995;102(5):401-406.
34. Vermylen J, Verhaegen-Declercq ML, Verstraete M, Fierens F. A double blind study of the effect of tranexamic acid in essential menorrhagia. Thromb Diath Haemorrh. 1968;20(3):583-587.
35. Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest. 1964;16:244-248.
36. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734-739.
37. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol. 1995;85(6):977-982.
38. Lukes AS, Muse K, Richter HE, Moore KA, Patrick DL. Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. Curr Med Res Opin. 2010;26(11):2673-2678.
39. Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol. 2001;99(2):238-243.
40. Muse K, Lukes AS, Gersten J, Waldbaum A, Mabey RG, Trott E. Long-term evaluation of safety and health-related quality of life in women with heavy menstrual bleeding treated with oral tranexamic acid. Womens Health (Lond Engl). 2011;7(6):699-707.
41. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;4:CD000249.
42. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001; 86(2):714-715.
43. Rybo G. Tranexamic acid therapy: Effective treatment in heavy menstrual bleeding. Clinical update on safety. Therapeutic Advances. 1991;4:1-8.
44. Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: A case-control study using the General Practice Research Database. BJOG. 2009;116(1):91-97.
45. Kirschner R. A cost-benefit analysis of different therapeutic methods in menorrhagia. Tidsskr Nor Laegeforen. 1995;115(5):618-621.
46. National Collaborating Centre for Women's and Children's Health (UK). Heavy Menstrual Bleeding. London: RCOG Press; 2007.